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Over lifecycle, from development through all industrialization stages and then over manufacturing history across
multiple sites, a biotechnology product must show very high levels of quality consistency, as that is a prerequisite for safety and efficacy to patients (cf. ICH Q5E, 2004).
Bioanalytical similarity has acquired over the last years another meaning with the introduction of biosimilars:
products that in principle cannot be identical to their reference products as processes used and other design
options are not exactly identical, leading for example to minor differences in clinically inactive components.
However, biosimilars must be proven to be pharmacologically identical to their reference products.
The two extremes above, in terms of bioanalytical similarity, are often confounded. The classical use of
bioanalytical information is still today very limited in scope and aim. An analytical technique is often used to
determine the presence of a few species (e.g., glycoforms, isoforms, high-molecular weight aggregates) and
ignore information also captured in other regions of that particular analytical domain (e.g., impurity peaks and
their relative distribution). Moreover, small variations of the entire fingerprint by one analytical technique over
several lots of the same product go completely unnoticed and may erroneously be attributed to minor variability
of method performance and not a change in the manufacturing process with a direct impact on product
differences.
Recently, FDA defined different levels of similarity (Draft Guidance, May 2014, “Clinical Pharmacology Data to
Support a Demonstration of Biosimilarity to a Reference Product”) namely the concepts of (1) “highly similar with
fingerprint-like similarity” and that of (2) “residual uncertainty” in regard to similarity.
Here we present a new approach to combine whole analytical domains from different techniques used to assess
similarity in biocomparability investigations that can (a) detect very small differences, (b) establish therefore high
levels of similarity and (c) assess residual uncertainties. We will illustrate our approach on reference products
over their lifecycle and to compare reference with putatively similar products. The outcome of assessments (a)
through (c) can then be linked to the pharmacological performance or both types of biotechnology products, and
support regulatory or other decisions related to managing filings.

